Risk-reduction strategies for platelet transfusion in the United States

TheScientificWorldJournal

Volumn 11, Issue , 2011, Pages 624-640

  Vamvakas, Eleftherios C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Apheresis platelets; Bleeding in hemato oncology patients; Intercept; Mirasol ; Multicomponent apheresis; Pathogen inactivation; Pathogen reduction; Platelet transfusion; Post transfusion bacteremia sepsis; Single donor platelets; Transfusion related acute lung injury (TRALI); Transfusion transmitted infections

Indexed keywords

APHERESIS; BACTEREMIA; BLEEDING; BLOOD DONOR; BLOODSTREAM INFECTION; ERYTHROCYTE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PLASMA; REVIEW; RISK REDUCTION; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TRANSFUSION ASSOCIATED BACTEREMIA SEPSIS; TRANSFUSION RELATED ACUTE LUNG INJURY; TRANSFUSION TRANSMITTED INFECTION; UNITED STATES;

HUMANS; PLATELET TRANSFUSION; RISK REDUCTION BEHAVIOR; UNITED STATES;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79955136367     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2011.60     Document Type: Review

References (82)

1. Vamvakas, E.C. and Blajchman, M.A. (2010) Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus. Med. Rev. 24, 77-124.
2. Menitove, J.E. and Shoos Lipton, K. (2009) Association Bulletin #09-04: Developments in Bacterial Testing and BBTS Standard 5.1.5.1. July 20, 2009. Available at: http://www.aabb.org/content/Members-Area/Association-Bulletins/ ab09-04.htm
3. Fredrick, J. and Shoos-Lipton, K. (2010) Association Bulletin #10-02: Interim Standard 5.1.5.1.1. May 3, 2010. Available at: http://www.aabb.org/ content/Members-Area/Association-Bulletins/ab10-02.htm
4. Vamvakas, E.C. (2009) Relative safety of pooled whole-blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 49, 2743-2758.
5. Ness, P.M. and Campbell-Lee, S.A. (2001) Single-donor versus pooled random-donor platelet concentrates. Curr. Opin. Hematol. 8, 392-396.
6. Ness, P.M., Braine, N., King, K., et al. (2001) Single-donor platelets reduce the risk of septic platelets transfusion reactions. Transfusion 41, 857-861. (Pubitemid 32642756)
7. Stramer, S.L., Glynn, S.A., Kleinman, S.H., et al. (2004) Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic-acid amplification testing. N. Engl. J. Med. 351, 760-768.
8. Stramer, S.L., Hollinger, F.B., Katz, L.M., et al. (2009) Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 49(Suppl 2), 1S-236S.
9. Lombardi, V.C., Ruscetti, F.W., Das Gupta, J., et al. (2009) Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 326, 530-531.
10. Whitaker, B.I., Green, J., King, M.R., et al. (2008) The 2007 Nationwide Blood Collection and Utilization Survey Report. Department of Health and Human Services, Washington, D.C. Available at: http://www.hhs.gov/ophs/bloodsafety/ 20076nbcus-survey.pdf
11. McCullough, J. (2007) Pathogen inactivation: a new paradigm for blood safety. Transfusion 47, 2180-2184.
12. Klein, H.G., Anderson, D., Bernardi, M.J., et al. (2007) Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 47, 2338-2347.
13. AuBuchon, J.P. (2010) Current status of pathogen inactivation methods. ISBT Sci. Ser. 5, 125-133.
14. Kerkhoffs, J.L.H., van Putten, W.L.J., Novotny, V.M.J., et al. (2010) Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br. J. Haematol. 150, 209-217.
15. The Mirasol Clinical Evaluation Study Group (2010) A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 50, 2362-2375.
16. Vamvakas, E.C. (2010) Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion. [Epub ahead of print]
17. Heuft, H.G., Mende, W., and Blasczyk, R. (2008) A general change of the platelet transfusion policy from apheresis platelet concentrates to pooled platelet concentrates is associated with a sharp increase in donor exposures and infection rates. Transfus. Med. Hemother. 35, 106-113.
18. Lopez-Plaza, I., Weissfeld, J., and Triulzi, D.J. (1999) The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 39, 925-932.
19. Zou, S., Musavi, F., Notari, E., Stramer, S., and Dodd, R. (2010) Prevalence, incidence, and residual risk of major blood-borne infections among apheresis collections to the American Red Cross Blood Services, 2004-2008. Transfusion 50, 1487-1494.
20. Wang, B., Schreiber, G.B., Glynn, S.A., et al. (2005) Does prevalence of transfusion-transmitted viral infection reflect corresponding incidence in United States blood donors? Transfusion 45, 1089-1096.
21. Kleinman, S.H. and Busch, M.P. (2006) Assessing the impact of HBV NAT on window-period reduction and residual risk. J. Clin. Virol. 36(Suppl), S523-S529.
22. Chudy, M., Schmidt, M., Czudai, V., et al. (2006) Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology 44, 99-107. (Pubitemid 44049143)
23. Yomtovian, R.A., Palavecino, E.L., Dysktra, A.H., et al. (2006) Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion 46, 719-730.
24. Kleinman, S.H., Kamel, H.T., Harpool, D.R., et al. (2006) Two-year experience with aerobic culturing of apheresis and whole-blood-derived platelets. Transfusion 46, 1787-1794. (Pubitemid 44435732)
25. Benjamin, R.J., Kline, L., Dy, B.A., et al. (2008) Bacterial contamination of whole-blood-derived platelets: the introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross. Transfusion 48, 2348-2355.
26. Benjamin, R.J. and Wagner, S.J. (2007) The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two-bottle culture systems and an estimation of false-negative culture rates. Transfusion 47, 1381-1389. (Pubitemid 47101084)
27. Murphy, W.G., Foley, M., Doherty, C., et al. (2008) Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternate approach to product safety. Vox Sang. 95, 13-19. (Pubitemid 351799415)
28. Schmidt, M., Hourfar, M.K., Nicol, S.B., et al. (2006) A comparison of three rapid bacterial detection methods under simulated real-life conditions. Transfusion 46, 1367-1373. (Pubitemid 44117965)
29. Kleinman, S., Grossman, B., and Kopko, P. (2010) A national survey of transfusion-related acute lung injury reduction policies for platelets and plasma in the United States. Transfusion 50, 1312-1321.
30. Dodd, R.Y. (2003) Emerging infections, transfusion safety, and epidemiology. N. Engl. J. Med. 349, 1205-1206.
31. van Rhenen, D., Gulliksson, H., Cazenave, J.P., et al. (2003) Transfusion of pooled buffy-coat platelet components prepared with a photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 101, 2426-2433. (Pubitemid 36302092)
32. McCullough, J., Vesole, D.H., Benjamin, R.J., et al. (2004) Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 104, 1534-1541. (Pubitemid 39166535)
33. Janetzko, K., Cazenave, J.P., Kluter, H., et al. (2005) Therapeutic efficacy and safety of photochemically-treated apheresis platelets processed with an optimized integrated set. Transfusion 45, 1443-1452. (Pubitemid 44194647)
34. Trotti, A., Byhardt, R., Stetz, J., et al. (2000) Common toxicity criteria version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 47, 13-47.
35. Miller, A.B., Hoogstraten, B., Staquet, M., and Winkler, A. (1981) Reporting results of cancer treatment. Cancer 47, 207-214. (Pubitemid 11167383)
36. Heddle, N.M. (2010) Optimal timing and dosing of platelet transfusions. ISBT Sci. Ser. 5, 88-94.
37. Snyder, E., McCullough, J., Slichter, S.J., et al. (2005) Clinical safety of platelets photochemically-treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 45, 1864-1875. (Pubitemid 43971413)
38. Murphy, S., Snyder, E., Cable, R., et al. (2006) Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 46, 24-33. (Pubitemid 43381781)
39. Slichter, S.J., Kaufman, R.M., Assmann, S.F., et al. (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. N. Engl. J. Med. 362, 600-613.
40. Picker, S.M., Schneider, V., and Gathof, B.S. (2009) Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen-reduction technologies. Transfusion 49, 1224-1232.
41. Picker, S.M., Oustianskaia, L., Schneider, V., and Gathof, B.S. (2009) Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen reduction. Vox Sang. 97, 26-33.
42. Lozano, M., Knutson, N., Tardivel, R., et al. (2010) A multicenter study of therapeutic efficacy and safety of platelet components prepared with pathogen inactivation (Intercept) stored for 6-7 days prior to transfusion. Vox Sang. 99(Suppl 1), 13.
43. Vamvakas, E.C. (2011) Universal white-blood-cell reduction in Europe: has transmission of vCJD been prevented? Transfus. Med. Rev., 25, 133-144.
44. th Meeting of the Spongiform Encephalopathy Advisory Committee, London, U.K., March 5, 2010. Available at: http://www.seac.gov.uk/summaries/seac104-summary.pdf
45. Chohan, G., Llewelyn, C., Mackenzie, J., et al. (2010) Variant Creutzfeldt-Jacob disease in a transfusion recipient: coincidence or cause? Transfusion 50, 1003-1006.
46. Houston, F., McCutcheon, S., Goldmann, W., et al. (2008) Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 112, 4739-4745.
47. University of Edinburgh. UK Creutzfeldt-Jakob Disease Surveillance Unit. Available at: http://www.cjd.ed.ac.uk
48. Turner, M.L. and Ludlam, C.A. (2009) An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br. J. Haematol. 144, 14-23.
49. SEAC (2006) Position statement. Position statement on TSE infectivity in blood. Spongiform Encephalopathy Advisory Committee, London, 2006 [Updated 2006 August 21]. Available at: http://www.seac.gov.uk/statements/statement0806.htm
50. Kleinman, S., Caulfield, T., Chan, P., et al. (2004) Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 44, 1774-1789. (Pubitemid 39644064)
51. Robillard, P., Hyson, C., and McCombie, N. (2007) TRALI, possible TRALI and respiratory complications of transfusion reported to the Canadian Transfusion-Transmitted Injuries Surveillance System. Transfusion 47(Suppl), 5A.
52. Eder, A.F., Herron, R., Strupp, A., et al. (2007) Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 47, 599-607.
53. Gajic, O., Rana, R., Winters, J.L., et al. (2007) Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am. J. Respir. Crit. Care Med. 176, 886-891.
54. Toy, P., Popovsky, M.A., Abraham, E., et al. (2005) Transfusion-related acute lung injury: definition and review. Crit. Care Med. 33, 721-726.
55. Strong, D.M. and Shoos Lipton, K. (2006) Transfusion-Related Acute Lung Injury. AABB Association Bulletin #06-07 (November 3, 2006). Available at: http://www.aabb.org/Content/Members-Area/Association-Bulletins/
56. Triulzi, D.J., Kleinman, S., Kakaiya, R.M., et al. (2009) The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 49, 1825-1835.
57. FDA/CBER (2010) Fatalities Reported to FDA Following Blood Collection and Transfusion. Annual Summary for Fiscal Year 2009. Available at: http://www.fda.gov/download/BiologicsBloodVaccines/SafetyAvailability/ ReportProblem/TransfusionDonationFatalities/UCM205620.pdf
58. Wiersum-Osselton, J.C., Middelburg, R.A., Beckers, E.A.M., et al. (2010) Male-only fresh frozen plasma for transfusion-related acute lung injury prevention. Transfusion. [Epub ahead of print]
59. Wright, S.E., Snowden, C.P., Athey, S.C., et al. (2008) Acute lung injury after abdominal aortic aneurysm repair: the effect of excluding donations from females from the production of fresh-frozen plasma. Crit. Care Med. 36, 1796-1802.
60. Nakazawa, H., Ohnishi, H., Okazaki, H., et al. (2009) Impact of fresh-frozen plasma from male-only donors versus mixed-sex donors on postoperative respiratory function in surgical patients: a prospective case-control study. Transfusion 49, 2434-2441.
61. Welsby, I.J., Troughton, M., Phillips-Bute, B., et al. (2010) The relationship of plasma transfusion from female and male donors with outcome after cardiac surgery. J. Thorac. Cardiovasc. Surg. 140, 1353-1360.
62. Middleburg, R.A., van Stein, D., Briet, E., and van der Born, J.G. (2008) The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury. Transfusion 48, 2167-2176.
63. Win, N., Chapman, C.E., Bowles, K.M., et al. (2008) How much residual plasma may cause TRALI? Transfus. Med. 18, 276-280.
64. van Stein, D., Beckers, E.A., Sintnicolaas, K., et al. (2010) Transfusion-related acute lung injury in the Netherlands: an observational study. Transfusion 50, 213-220.
65. Popovsky, M.A. (2008) Transfusion-related acute lung injury: incidence, pathogenesis, and the role of multicomponent apheresis in its prevention. Transfus. Med. Hemother. 35, 76-79.
66. Popovsky, M.A. (2005) Multicomponent apheresis blood collections in the United States: current status and future directions. Transfus. Apher. Sci. 3, 299-304.
67. Zingsem, J. (2010) Multicomponent apheresis. ISBT Sci. Ser. 5, 83-87.
68. Devine, D., Jenkins, G., Howe, D., and Goldman, M. (2010) Relative safety of buffy-coat platelet pools. Transfusion 50, 1591-1592.
69. Schrezenmeier, H. and Seifried, E. (2010) Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang. 99, 1-15.
70. Middelburg, R.A., van Stein, D., Zupanska, B., et al. (2010) Female donors and transfusion-related acute lung injury. Transfusion 50, 2447-2454.
71. Vamvakas, E.C. (2010) The ethics of wasting the donor's gift of buffy coat. Vox Sang. 100, 256-257.
72. Kamel, H., Tomasulo, P., Bravo, M., et al. (2010) Delayed adverse reactions to blood donation. Transfusion 50, 556-565.
73. Osselaer, J.C., Messe, N., Hervig, T., et al. (2008) A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 48, 1061-1071. (Pubitemid 351793479)
74. Osselaer, J.C., Cazenave, J.P., Lambermont, M., et al. (2008) An active hemovigilance program characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang. 94, 315-323. (Pubitemid 351535733)
75. McDonald, C.P. and Blajchman, M.A. (2008) Bacterial contamination in blood and blood components. In Transfusion Microbiology. Barbara, J.A.J., Regan, F.A.M., and Contreras, M.C., Eds. Cambridge University Press, Cambridge. pp. 87-115.
76. rd International StKB Future Workshop on Hemotherapy and Cell Therapy, November 11, 2010, Hannover, Germany. Heim, M. and Hitzler, W., Chairs.
77. Kleinman, S., Dumont, L.J., Tomasulo, P., et al. (2009) The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. Transfusion 49, 903-912.
78. Kuehnert, M.J., Roth, V.R., Haley, N.R., et al. (2001) Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 41, 1493-1499. (Pubitemid 34072672)
79. Eder, A.F., Kennedy, J.M., Dy, B.A., et al.; American Red Cross Regional Blood Centers (2007) Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 47, 1134-1142. (Pubitemid 46934307)
80. Schmidt, M. (2009) Comparison of different methods of bacterial detection in blood components. ISBT Sci. Ser. 4, 80-86.
81. Simonsen, A.C., Johansson, P.I., Conlan, M.G., et al. (2006) Transfusion of 7-day-old amotosalen photochemically-treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 46, 424-433. (Pubitemid 43334097)
82. BPAC Meeting: 11/16-11/17/09. Study Designs (Phases III and IV) for Product Development of Human Platelets Using the Cerus INTERCEPT Blood System for Pathogen Inactivation. Available at: http://www.aabb.org/events/government/ bpac/Pages/bpacmeeting111609.aspx